AptaTargets Overview

  • Year Founded
  • 2014

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 10

Employees

  • Latest Deal Type
  • 2ndary - Private

  • Investors
  • 5

AptaTargets General Information

Description

Developer of aptamer-based therapeutics intended to treat acute conditions driven by inflammation. The company offers drug candidates targeting specific molecular pathways and inflammation mechanisms, enabling healthcare providers and researchers to address conditions such as stroke and cardiovascular disorders with targeted treatment approaches.

Contact Information

Website
www.aptatargets.com
Ownership Status
Acquired/Merged
(Operating Subsidiary)
Financing Status
Venture Capital-Backed
Corporate Office
  • Avenida Cardenal Herrera Oria, 298-1 A C.P.
  • 28035 Madrid
  • Spain
+34 910
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Parent Company
Bayer
Vertical(s)
LOHAS & Wellness, HealthTech, Life Sciences
Corporate Office
  • Avenida Cardenal Herrera Oria, 298-1 A C.P.
  • 28035 Madrid
  • Spain
+34 910

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

AptaTargets Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
13. Secondary Transaction - Private 11-May-2025 Completed Clinical Trials - Phase 2
12. Accelerator/Incubator 11-Mar-2024 Completed Clinical Trials - Phase 2
11. Grant 19-Feb-2024 Completed Clinical Trials - Phase 2
10. Later Stage VC 23-Dec-2021 Completed Clinical Trials - Phase 2
9. Later Stage VC (Series B) 14-Oct-2020 Completed Clinical Trials - Phase 1
8. Merger/Acquisition 01-Jan-2020 Completed Clinical Trials - Phase 1
7. Later Stage VC 02-Aug-2019 Completed Clinical Trials - Phase 1
6. Grant 01-Dec-2018 Completed Clinical Trials - Phase 1
5. Early Stage VC (Series A) 15-Aug-2018 $3.13M $5.78M Completed Clinical Trials - Phase 1
4. Early Stage VC 15-Mar-2017 $2.43M $2.65M Completed Clinical Trials - Phase 1
To view AptaTargets’s complete valuation and funding history, request access »

AptaTargets Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Ordinary
Series C
Series C
Ordinary
Series A
Ordinary
Ordinary 27,433 $0.011288 $5.23 $5.23 1x $5.23 1.52%
Ordinary 17,288 $0.011288 $6.44 $6.44 1x $6.44 0.96%
To view AptaTargets’s complete cap table history, request access »

AptaTargets Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of aptamer-based therapeutics intended to treat acute conditions driven by inflammation. The company offers dr
Drug Discovery
Madrid, Spain
10 As of 2020

Cambridge, MA

Modiin, Israel
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

AptaTargets Competitors (50)

One of AptaTargets’s 50 competitors is AnTolRx, a Formerly VC-backed company based in Cambridge, MA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
AnTolRx Formerly VC-backed Cambridge, MA
BioLineRx Formerly VC-backed Modiin, Israel
Amal Therapeutics Formerly VC-backed Geneva, Switzerland
Endeavor BioMedicines Venture Capital-Backed San Diego, CA
Cidara Therapeutics Formerly VC-backed San Diego, CA
You’re viewing 5 of 50 competitors. Get the full list »

AptaTargets Patents

  • 14

    Total Documents Applications and Grants

  • Total Patents Families

  • 7

    Granted

  • 2

    Pending

  • Expiring in next 12 mo

AptaTargets Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2024240750-A1 New tlr-4 antagonist aptamers Inactive 22-May-2023
WO-2024146930-A1 Aptoll molecules for the treatment of ischemic stroke and intracranial hemorrhages Inactive 05-Jan-2023
WO-2020230108-A1 Treatment of ischemic stroke with aptamers targeting tlr-4 Inactive 16-May-2019
CA-3140285-A1 Treatment of tlr-4 mediated diseases and conditions with aptamers targeting tlr-4 Pending 16-May-2019
WO-2020230109-A1 Treatment of tlr-4 mediated diseases and conditions with aptamers targeting tlr-4 Inactive 16-May-2019 A61K31/711
To view AptaTargets’s complete patent history, request access »

AptaTargets Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

AptaTargets Former Investors (6)

Investor Name Investor Type Holding Investor Since Participating Rounds
Caixa Capital Risc Corporate Venture Capital Minority
Criteria Bio Ventures Venture Capital Minority
Growth Factor BioCapital Venture Capital Minority
Inveready Asset Management Venture Capital Minority
Ministerio de Economía, Industria y Competitividad Government
You’re viewing 5 of 6 investors. Get the full list »

Ready to get started?

Request a free trial

AptaTargets FAQs

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process